Relationship Between Macular Thickness Measurement and Signal Strength in Optical Coherence Tomography

Optical Tomography Clinical Trial

Official title:

Relationship Between Macular Thickness Measurement and Signal Strength Using Stratus Optical Coherence Tomography

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01115881
• Other study ID #: OCT-1
• Status: Completed
• Phase: N/A
• First received: May 2, 2010
• Last updated: September 26, 2016
• Start date: May 2010
• Est. completion date: May 2013

Study information

• Verified date: January 2010
• Source: Meir Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Signal strength is a parameter introduced in analysis software version 4.0.1, of the OCT stratus, that combines SNR and uniformity of the signal within a scan The scale of signal strength ranges from 1 to 10, with 1 representing poor image quality and 10 representing excellent image quality It has been showed that signal strength has a better image quality discriminating ability than SNR The operation manual recommends a minimum signal strength of 5 for macular thickness measurement There is no consensus on the level of signal strength above which should be considered to be good quality The inclusion Criteria for acceptable signal strength varies widely in the literature the purpose of our study is to examine the relationship between signal strength and macular thickness measured by stratus OCT

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: May 2013
• Est. primary completion date: May 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• healthy subjects in this study other than refractive error, all included eyes had no concurrent ocular pathologic features BCVA of at least 20/30, and had spherical refractive error within the range of

• 4.00 D to 4.00 D

Exclusion Criteria:

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Optical Tomography

Locations

Country	Name	City	State
Israel	Meir medical center	Kfar-Saba

Sponsors (1)

Lead Sponsor	Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel,